SCHEMBL615095

SCHEMBL615095

COc1ccc(C)cc1C(CCO)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
LMNA P02545 2/20 0.46
CHRM2 P08172 2/20 0.46
CHRM5 P08912 2/20 0.46
CHRM1 P11229 2/20 0.46
CHRM3 P20309 2/20 0.46
HRH1 P35367 2/20 0.46
ESR1 P03372 1/20 0.46
CHRM4 P08173 1/20 0.46
KCNE1 P15382 1/20 0.46
PTGS1 P23219 1/20 0.46
HRH2 P25021 1/20 0.46
HTR2A P28223 1/20 0.46
SLC6A4 P31645 1/20 0.46
ADRA1A P35348 1/20 0.46
OPRK1 P41145 1/20 0.46
KCNQ1 P51787 1/20 0.46
KCNH2 Q12809 1/20 0.46
CACNA1C Q13936 1/20 0.46
SCN5A Q14524 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9226011 0.90 TSHR (0.43) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL11387106 0.84 MEN1 (0.50) LMNASLC6A4KMT2AMEN1L3MBTL1
SCHEMBL9231158 0.84 LMNA (0.50) MAPTLMNASLC6A4ALDH1A1L3MBTL1
SCHEMBL4064320 0.83 PTGER1 (0.44) MAPTLMNACHRM2CHRM5CHRM1
SCHEMBL12121777 0.83 PTGER1 (0.44) MAPTLMNACHRM2CHRM5CHRM1
SCHEMBL579976 0.83 CHRM2 (0.46) MAPTLMNACHRM2CHRM1KMT2A
SCHEMBL580492 0.83 CHRM2 (0.46) MAPTLMNACHRM2CHRM1KMT2A
SCHEMBL579637 0.83 CHRM2 (0.46) MAPTLMNACHRM2CHRM1KMT2A
SCHEMBL579703 0.82 CYP1A2 (0.43) MAPTKMT2AMEN1TNFTSHR
SCHEMBL580496 0.82 CYP1A2 (0.43) MAPTKMT2AMEN1TNFTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010092500-A2 A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE ALEMBIC LIMITED (IN) 2010-08-19 WO claimed
WO-2010046801-A2 A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE ALEMBIC LIMITED (IN) 2010-04-29 WO claimed
EP-1419135-A4 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LAB LTD (IN) 2006-01-11 EP claimed
US-20040249211-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES LIMITED (IN) 2004-12-09 US claimed
US-6822119-B1 REACTING 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH DIMETHYL SULFATE USING PHASE TRANSFER CATALYST; DESTERIFICATION, REDUCTION, AMINATION, SULFONATION, DEPROTECTING, DECYCLIZATION, AND SALT FORMATION RANBAXY LABORATORIES LIMITED (IN) 2004-11-23 US claimed
EP-1419135-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES, LTD. (IN) 2004-05-19 EP claimed
WO-2003014060-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES LIMITED (IN) 2003-02-20 WO claimed
EP-1927585-B1 METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES INTERQUIM SA (ES) 2016-07-27 EP disclosed
US-9085509-B2 Process for preparing fesoterodine ALEMBIC PHARMACEUTICALS LIMITED (IN) 2015-07-21 US disclosed
US-9085509-B2 Process for preparing fesoterodine ALEMBIC PHARMACEUTICALS LIMITED (IN) 2015-07-21 US disclosed
EP-2686288-B1 A PROCESS FOR PREPARING FESOTERODINE ALEMBIC PHARMACEUTICALS LTD (IN) 2015-03-25 EP disclosed
US-20140039216-A1 PROCESS FOR PREPARING FESOTERODINE ALEMBIC PHARMACEUTICALS LIMITED (IN) 2014-02-06 US disclosed
US-20140039216-A1 PROCESS FOR PREPARING FESOTERODINE ALEMBIC PHARMACEUTICALS LIMITED (IN) 2014-02-06 US disclosed
EP-1698615-A1 METHOD OF OBTAINING TOLTERODINE Ragactives, S.L. (ES) 2006-09-06 EP disclosed
US-20060094904-A1 Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol DR. REDDY'S LABORATORIES LIMITED (IN) 2006-05-04 US disclosed
EP-1419135-A4 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LAB LTD (IN) 2006-01-11 EP disclosed
US-20040249211-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES LIMITED (IN) 2004-12-09 US disclosed
US-6822119-B1 REACTING 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH DIMETHYL SULFATE USING PHASE TRANSFER CATALYST; DESTERIFICATION, REDUCTION, AMINATION, SULFONATION, DEPROTECTING, DECYCLIZATION, AND SALT FORMATION RANBAXY LABORATORIES LIMITED (IN) 2004-11-23 US disclosed
EP-1419135-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES, LTD. (IN) 2004-05-19 EP disclosed
WO-2003014060-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES LIMITED (IN) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140039216-A1 PROCESS FOR PREPARING FESOTERODINE FES, QDPR, CYP4F3 MAPT 1650/4885LMNA 4676/4885CHRM2 417/4885
US-20060094904-A1 Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol ADRB3, UGT1A3, COMT MAPT 400/4885LMNA 2719/4885CHRM2 292/4885
US-20040249211-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE ADRB3, ADRA1B, ADRA2B MAPT 1099/4885LMNA 4055/4885CHRM2 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.